Congress Abstracts

2020 – SITC – NBTXR3 with Anti-PD-1 Therapy

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver, Lung

Cancer immunotherapies have shown promising clinical outcomes; however, the majority of patients are non-responders or will develop resistance during the course of treatment. One of the current challenges is to increase the response rate to immune checkpoint inhibitors (ICIs). Combining immunotherapy with radiation therapy (RT) is emerging as a valuable strategy to prime the immune response. However, RT dose and ultimate efficacy are limited by toxicity related to exposure of healthy tissues. […]

2020 – SITC – NBTXR3 From Bench to Bedside

Clinical Data NBTXR3, Congress Abstracts, In Vitro in Vivo NBTXR3

Despite recent advances, resistance to immune checkpoint inhibitors (ICI), observed in over 80% of treated patients, is currently the main challenge immuno-oncology is facing. Intense efforts are being made to identify combination therapies that could improve ICI response rates. Administered intratumorally, NBTXR3 enhances the energy dose deposited by ionizing radiation within tumor cells, increasing the anti-tumor efficacy of radiation therapy (XRT) without adding toxicity to surrounding tissues. […]

2020 – ESTRO – NBTXR3 for the Treatment of Locally Advanced HNSCC

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

Elderly and frail patients (pts) with head and neck squamous cell carcinoma (HSNCC) remain a challenging population to manage due to the lack of evidence-based recommendations. Despite representing approximately 20% of the HNSCC population no consensus exists on the optimal treatment for these pts with locally advanced (LA) disease, vulnerable to current standard of care treatment-induced toxicities. New approaches are thus needed to improve clinical outcomes without adding toxicity. NBTXR3 hafnium oxide nanoparticles injected intratumorally may represent such an option. […]

2020 – ASTRO – NBTXR3 in HNSCC

Clinical Data NBTXR3, Congress Abstracts

Concurrent chemoradiation (CRT) with high dose cisplatin or cetuximab in case of contra-indication to cisplatin is the standard of care non-surgical approach for patients (pts) with locally advanced head and neck squamous cell carcinoma (LA HNSCC). Older age is a contra-indication to cisplatin and survival in older pts might not improve with cetuximab. The development of new treatment options for elderly pts with LA HNSCC is therefore urgently needed. […]

2020 – ASTRO – NBTXR3 in Advanced Liver Cancers

Clinical Data NBTXR3, Congress Abstracts, Liver

Stereotactic body radiotherapy (SBRT) is a well-tolerated and valuable alternative for patients with unresectable hepatocellular carcinoma (HCC) or liver metastases (mets) who are not eligible for standard treatment such as surgery, local ablation or chemoembolization. Yet, the energy dose delivered to the tumor is limited due to potential toxicity to healthy tissues and the need to preserve liver function. […]

2020 – ASTRO – NBTXR3 in Combination with Anti-PD-1

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver, Lung

Immune checkpoint inhibitors (ICIs) are being increasingly used to improve patient outcomes across different cancer types. However, the response rate to ICIs remains low (~15%), indicating the need for novel strategies to improve treatment outcome. Emerging evidence suggests that radiation therapy (RT) could potentially enhance the antitumor response and provide synergy with ICIs. RT dose and ultimate efficacy are however limited by toxicity related to exposure of healthy tissues. […]

2020 – ESMO – NBTXR3 in HCC and Liver Metastases

Clinical Data NBTXR3, Congress Abstracts, Liver

NBTXR3, functionalized hafnium oxide nanoparticles, administered by intratumoral injection (ITI) and activated by radiotherapy (RT), such as stereotactic body RT (SBRT), increases energy deposit inside tumor cells and subsequently tumor cell death compared to RT alone, while sparing healthy tissues. This innovative approach, which does not engage liver and renal functions, might benefit patients (pts) with unresectable liver cancers. […]

2020 – ASCO – NBTXR3 With Anti PD1 Therapy

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver, Lung

Despite the past decade of transformative advances in immuno-oncology, the response rate to checkpoint inhibitors (ICIs) remains low (~15%). There is significant interest in developing strategies to overcome resistance to these treatments, thus increasing response rate. Emerging evidence suggests that radiation therapy (RT) could potentially augment the antitumor response to ICIs through synergic effect. […]

2020 – MHNCS – NBTXR3 for locally advanced HNSCC

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

Elderly and/or frail patients (pts) with head and neck squamous cell carcinoma (HSNCC) remain a challenging to manage and neglected population regarding clinical trials and data generation to support treatment choices. Despite representing 20% of the HNSCC population no consensus exists on what is the optimal treatment for these pts with locally advanced (LA) disease, vulnerable to treatment-induced toxicities with the current standard of care. […]

2020 – ASCO-SITC – NBTXR3 with anti-PD-1 therapy

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver, Lung

Most cancer patients present resistance to immune therapy; only approximately 15% of patients respond to immune checkpoint inhibitors (ICI). Strategies able to increase ICI response are thus of great interest. Radiotherapy (RT), by acting as an immunomodulator is a good candidate to increase the proportion of ICI responders. However, RT dose and ultimate efficacy are limited by potential toxicity to healthy tissues. NBTXR3, a first in class radioenhancer administered by intratumoral injection, has been designed at the nanoscale to increase RT energy dose deposition within the tumor. […]

Congresses are a key element for Nanobiotix to publish scientific data and results. This section lists abstracts that have been published by Nanobiotix over the last decade.